The DECLARE, CANVAS and EMPA-REG CV outcomes trials assessing the SGLT2 inhibitors dapagliflozin (Farxiga, AstraZeneca), canagliflozin (Invokana, Janssen) and empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), respectively, all showed CV and renal benefit in adults with type 2 diabetes with established CVD, DeFronzo said
A 2022 study involving people with Irritable Bowel Syndrome (IBS) found that ROSE 010, a GLP-1 receptor agonist, reduced IBS pain during flare-ups, primarily in female participants
FAQ 5: I already did fertility treatments while on GLP-1sam I in trouble
In a more recent publication, Lin et al
Thymosin Beta 4 (TB4) is a naturally occurring peptide in our thymus gland, and one of the key players in immune modulation and tissue regeneration